Salient Pharmaceuticals Incorporated Report issue

For profit Phase 2
Founded: Houston TX United States (2007)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2012
NCT01570634
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

calcium (1 trial)

sodium aluminosilicate (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Neuroendocrine (Phase 2)

Clostridium Infections (Phase 2)

Diarrhea (Phase 2)

Infections (Phase 2)

Thyroid Diseases (Phase 2)

Thyroid Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2